Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$24.38 USD

24.38
1,611,692

+0.23 (0.95%)

Updated May 20, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

Perrigo (PRGO) delivers mixed second-quarter 2022 results. Higher demand for cough/cold products continues during the reported quarter. Unfavorable currency movements hurt sales and earnings.

Karuna (KRTX) Lags on Q2 Earnings, Up 71% on Schizophrenia Data

Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Shockwave Medical (SWAV) Beats on Q2 Earnings & Revenues

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and expansion in gross margin.

Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth

Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.

DENTSPLY SIRONA (XRAY) Up on Strong Q2 Preliminary Results

DENTSPLY SIRONA's (XRAY) preliminary second-quarter 2022 results reflect the normalizing business, aided by product launches and pricing adjustments. Shares rise.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss

Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark

According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.

QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.

AMN Healthcare (AMN) Q2 Earnings, Revenues Beat Estimates

AMN Healthcare's (AMN) robust Q2 results demonstrate its segmental strength.

Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat

Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.

Agios (AGIO) Q2 Loss Narrower Than Expected, Sales Beat

Agios Pharmaceuticals' (AGIO) posts encouraging results for the second quarter. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.

bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss

bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips

Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.

Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates

Change Healthcare's (CHNG) fiscal first-quarter 2023 results benefit from solid performance across Software and Analytics, Network Solutions and Enterprise Imaging segments.

LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates

LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.

Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance

Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.

PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.

Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat

Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.